๎๊ฒ์
๎๊ฒ์
๎
Akoustis Technologies Ord Shs
AKTS๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
18.090USD
+0.250+1.40%
์ข
๊ฐย 04/15, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
2.80B์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Akoustis Technologies Ord Shs ํ์ฌ
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Akoustis Technologies Ord Shs ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ AKTS
ํ์ฌ ์ด๋ฆAktis Oncology Inc
์์ฅ์ผJan 09, 2026
CEORoden (Matthew)
์ง์ ์117
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJan 09
์ฃผ์17 Drydock Avenue
๋์BOSTON
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02210
์ ํ13026587581
์น์ฌ์ดํธhttps://www.aktisoncology.com/
์ข
๋ชฉ ์ฝ๋ AKTS
์์ฅ์ผJan 09, 2026
CEORoden (Matthew)
Akoustis Technologies Ord Shs์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
Ms. Helen S. Kim
Ms. Helen S. Kim
Independent Director
Independent Director
--
--
Dr. Andrew Levin, M.D., Ph.D.
Dr. Andrew Levin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mr. Lloyd M. Segal
Mr. Lloyd M. Segal
Independent Director
Independent Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
์์ต ๋ถ์
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Jan 10
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Jan 10
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ง์ญ๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Asia
5.84M
64.74%
Americas
2.43M
26.95%
Europe
750.00K
8.31%
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: 2 hours ago
๋ง์ง๋ง ์
๋ฐ์ดํธ: 2 hours ago
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
MPM BioImpact LLC
19.21%
Eli Lilly and Company
11.88%
VV Manager LLC
10.92%
EcoR1 Capital, LLC
9.03%
BlackRock Institutional Trust Company, N.A.
1.19%
๊ธฐํ
47.76%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
MPM BioImpact LLC
19.21%
Eli Lilly and Company
11.88%
VV Manager LLC
10.92%
EcoR1 Capital, LLC
9.03%
BlackRock Institutional Trust Company, N.A.
1.19%
๊ธฐํ
47.76%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor/Hedge Fund
28.97%
Corporation
11.88%
Venture Capital
10.92%
Investment Advisor
2.21%
Individual Investor
0.40%
๊ธฐํ
45.62%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Jan 10
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Jan 10
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2026Q1
184
21.93M
41.01%
-7.10M
2025Q4
188
74.33K
0.05%
-32.41M
2025Q3
209
74.33K
0.05%
-35.90M
2025Q2
236
74.33K
0.05%
-41.95M
2025Q1
251
315.89K
0.20%
-42.44M
2024Q4
266
839.61K
0.54%
-43.07M
2024Q3
283
21.16M
13.70%
-24.03M
2024Q2
288
25.38M
23.18%
-30.85M
2024Q1
283
43.24M
43.52%
-1.29M
2023Q4
287
31.11M
40.06%
-14.76M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
MPM BioImpact LLC
10.26M
19.21%
+10.26M
--
Jan 12, 2026
Eli Lilly and Company
6.34M
11.88%
+6.34M
--
Jan 12, 2026
VV Manager LLC
5.83M
10.92%
+5.83M
--
Jan 12, 2026
EcoR1 Capital, LLC
4.82M
9.03%
+4.82M
--
Jan 12, 2026
Fidelity Management & Research Company LLC
555.55K
1.04%
+555.55K
--
Jan 31, 2026
Wellington Management Company, LLP
208.41K
0.39%
+208.41K
--
Jan 31, 2026
Driehaus Capital Management, LLC
143.14K
0.27%
+143.14K
--
Jan 31, 2026
Feldman (Paul L. Ph.D.)
118.28K
0.22%
+118.28K
--
Jan 09, 2026
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Jan 10
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Jan 10
์ด๋ฆ
๋น์จ
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
๋น์จ0%
Avantis US Small Cap Equity ETF
๋น์จ0%
iShares Micro-Cap ETF
๋น์จ0%
iShares Russell 2000 Growth ETF
๋น์จ0%
iShares Russell 2000 ETF
๋น์จ0%
iShares Russell 3000 ETF
๋น์จ0%
Global X Russell 2000 ETF
๋น์จ0%
ProShares UltraPro Russell2000
๋น์จ0%
Proshares Ultra Russell 2000
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
